[144] Confluent, Inc. SEC Filing

Rhea-AI Filing Summary

Confluent, Inc. (CFLT) Form 144: This notice reports a proposed sale of 465,000 common shares through Morgan Stanley Smith Barney, with an aggregate market value of $8,941,950 based on the filing. The shares represent a portion of total outstanding common shares of 291,931,187 and are scheduled for sale on 09/04/2025 on NASDAQ. The filing indicates the shares were acquired as Founders Shares on 09/27/2019 and were paid for in cash at acquisition.

The filing also discloses recent 10b5-1 sales by the same person in the past three months: 232,500 shares on 06/05/2025 (gross proceeds $5,695,203.75), 232,500 shares on 08/14/2025 (gross proceeds $3,993,675.75), and 37,707 shares on 08/20/2025 (gross proceeds $642,429.24). The notice includes the standard Rule 144 and 10b5-1 representations but provides no additional operational or financial disclosures about Confluent.

Positive

• Clear disclosure of the proposed sale amount (465,000 shares) and broker (Morgan Stanley Smith Barney).
• Acquisition details provided: shares were acquired as founders shares on 09/27/2019, with cash payment noted.
• Recent 10b5-1 sales fully listed with dates and gross proceeds, improving transparency about insider dispositions.

Negative

• Significant insider selling reported: proposed sale valued at $8,941,950 plus ~ $10.33M in gross proceeds from recent 10b5-1 sales in the past three months.
• No contextual company operational or financial information is provided in the filing to explain the sales or evaluate their implications.

Insights

Securities Analyst

TL;DR: Insider plans to sell 465,000 shares (~$8.94M) via Morgan Stanley; recent 10b5-1 sales total material cash proceeds.

This Form 144 details a proposed disposition of 465,000 common shares valued at $8.94 million, scheduled for 09/04/2025, executed through Morgan Stanley Smith Barney on NASDAQ. The securities were acquired as founders shares on 09/27/2019, indicating long-term holding prior to these sales. The filing also documents three 10b5-1 sales in the past three months totaling 502,707 shares and approximately $10.33 million in gross proceeds. From a market-impact perspective, the offered block equals roughly 0.16% of outstanding shares, while the recent cumulative insider sales provide concrete liquidity realized by the seller.

Corporate Governance Expert

TL;DR: Filing is procedurally complete and discloses use of 10b5-1 sales; no governance issues or undisclosed material information are stated.

The Form 144 contains required disclosures: identity of broker, class and amount of securities, acquisition date and nature (founders shares from 09/27/2019), and recent delegated 10b5-1 sales with dates and proceeds. The signer affirms no undisclosed material adverse information. The filing does not include any disclaimers, special conditions, or unusual payment arrangements. As presented, the document meets Rule 144 notice requirements and signals routine insider liquidity rather than a governance event.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	465000	8941950.00	291931187	09/04/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/27/2019	Founders Shares	Issuer			465000	09/27/2019	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for EDWARD JAY KREPS 899 W. EVELYN AVENUE MOUNTAIN VIEW CA 94041	Common	08/20/2025	37707	642429.24
10b5-1 Sales for EDWARD JAY KREPS 899 W. EVELYN AVENUE MOUNTAIN VIEW CA 94041	Common	08/14/2025	232500	3993675.75
10b5-1 Sales for EDWARD JAY KREPS 899 W. EVELYN AVENUE MOUNTAIN VIEW CA 94041	Common	06/05/2025	232500	5695203.75

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What is the size and value of the proposed sale in Confluent (CFLT) Form 144?

The filing proposes sale of 465,000 common shares with an aggregate market value of $8,941,950 scheduled for 09/04/2025 on NASDAQ.

Through which broker will the Confluent shares be sold?

The shares are to be sold through Morgan Stanley Smith Barney LLC, Executive Financial Services, 1 New York Plaza.

When were the shares being sold originally acquired?

The securities were acquired as Founders Shares on 09/27/2019 and payment was made in cash at acquisition.

Has the seller recently sold Confluent shares?

Yes. The filing lists 10b5-1 sales totaling 502,707 shares in the past three months with gross proceeds of about $10.33 million across sales on 06/05/2025, 08/14/2025, and 08/20/2025.

Does the filing state any undisclosed material adverse information about Confluent?

The signer represents they do not know any material adverse information about the issuer that has not been publicly disclosed.